Clinical Trial Update: Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A clinical trial registry update for a Phase 2 study of eribulin plus bevacizumab in advanced HER2-negative breast cancer, noting the study status as not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Wang Jiayu | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Status: NOT_YET_RECRUITING